dc.contributor.author |
Weisel, Katja |
|
dc.date.accessioned |
2020-04-15T08:43:20Z |
|
dc.date.available |
2020-04-15T08:43:20Z |
|
dc.date.issued |
2019 |
|
dc.identifier.issn |
1471-2407 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/99563 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Bmc |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1186/s12885-019-5600-x |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20190926111821_01310 |
|
utue.personen.roh |
Salwender, Hans |
|
utue.personen.roh |
Bertsch, Uta |
|
utue.personen.roh |
Weisel, Katja |
|
utue.personen.roh |
Duerig, Jan |
|
utue.personen.roh |
Kunz, Christina |
|
utue.personen.roh |
Benner, Axel |
|
utue.personen.roh |
Blau, Igor W. |
|
utue.personen.roh |
Raab, Marc Steffen |
|
utue.personen.roh |
Hillengass, Jens |
|
utue.personen.roh |
Hose, Dirk |
|
utue.personen.roh |
Huhn, Stefanie |
|
utue.personen.roh |
Hundemer, Michael |
|
utue.personen.roh |
Andrulis, Mindaugas |
|
utue.personen.roh |
Jauch, Anna |
|
utue.personen.roh |
Seidel-Glaetzer, Andrea |
|
utue.personen.roh |
Lindemann, Hans-Walter |
|
utue.personen.roh |
Hensel, Manfred |
|
utue.personen.roh |
Fronhoffs, Stefan |
|
utue.personen.roh |
Martens, Uwe |
|
utue.personen.roh |
Hansen, Timon |
|
utue.personen.roh |
Wattad, Mohammed |
|
utue.personen.roh |
Graeven, Ullrich |
|
utue.personen.roh |
Munder, Markus |
|
utue.personen.roh |
Fenk, Roland |
|
utue.personen.roh |
Haenel, Mathias |
|
utue.personen.roh |
Scheid, Christof |
|
utue.personen.roh |
Goldschmidt, Hartmut |
|
dcterms.isPartOf.ZSTitelID |
Bmc Cancer |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article 504 |
de_DE |
dcterms.isPartOf.ZS-Volume |
19 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |